Listing - June 19, 2014
Stock market premiere for Bactiguard
On June 19, Bactiguard entered Nasdaq OMX’s main list. The introduction price was in the lower intervall span. Bactiguard has determined the price for the stock market introduction to SEK 38 per B share. The main owners have also decided to reduce the number of shares in the offer which reduces the offer by approximately […]
Uncategorized - June 19, 2014
Akademiska first on gene analysis prediction of serious side effects from statins
Akademiska in Uppsala is the first Swedish hospital laboratory to analyze a certain gene variety that can predict an increased risk of severe muscle side effects during statin treatment. Statins are a common group of colesterol lowering medicines, used by approximately one out of ten adults to treat increased blood lipids and to prevent cardiovascular […]
Uncategorized - June 18, 2014
60 millions to young researchers
The Swedish Foundation for Strategic Research is allocating ten projects SEK 6 millions each in order to widen the recruitment base for younger promising researchers aspiring for top positions. The funding will be allocated for a five-year-period within the scope of the program “Underrepresented gender”. According to the Swedish Foundation for Strategic Research, SFF, the […]
Collaboration - June 18, 2014
Pfizer collaborates with Cellectis
The two companies have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies. Pfizer will get exclusive rights to pursue development and commercialization of CAR-T therapies, in the field of oncology, directed at a total of fifteen targets selected by Pfizer. Both companies will work together on preclinical research and Pfizer will […]
Agreement - June 18, 2014
BioGaia enters new agreements
The Swedish health care company has signed a distribution agreement for India and an exclusive agreement in the UK. BioGaia has signed a non-exclusive agreement with Pharma Base SA for the rights to sell BioGaia’s ProTectis Baby Drops in India. Under the agreement, Pharma Base will cooperate with a local distributor for the marketing and […]
Clinical Trials - June 18, 2014
Positive results from Lundbeck study
The Danish company has announced results from a connect study showing that Brintellix in adults with major depressive disorder met the primary study endpoint of demonstrating superiority versus placebo in cognivite function. The objectives of this randomized, double-blind, placebo-controlled study were to evaluate the effects of Brintellix on cognitive function using objective neuropsychological tests associated […]
